Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug

SILO Pharma, Inc. (Nasdaq: SILO) ("SILO" or "the Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that the Japan Patent Office has granted patent number 7683882 to SILO's research and licensing partner Columbia University for the invention titled "Prophylactic efficacy of serotonin 4 receptor agonists against stress," exclusively licensed to SILO by Columbia University. Columbia University recently received an Australian patent for the same invention.

The patent reinforces protection for Silo's lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD), originally developed by Columbia University.

"This Japanese patent adds another layer of protection for SPC-15, adding to our high-value international IP portfolio," said Silo CEO Eric Weisblum. "Our expanding patent library is a cornerstone in the ongoing development and regulatory strategy for our novel PTSD therapy."

About SPC-15

SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA's streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15.

About Silo Pharma

Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company's portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Silo's research is conducted in collaboration with leading universities and laboratories. silopharma.com

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words "could", "believe", "anticipate", "intend", "estimate", "expect", "may", "continue", "predict", "potential", and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. ("Silo" or "the Company") to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company's technology platforms, retaining and expanding the Company's customer base, fluctuations in consumer spending on the Company's products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.

Contact

800-705-0120
investors@silopharma.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

SILO
The Conversation (0)
Silo Wellness Submits CSE Listing Statement for Review of Born Defense Proposed Change of Business

Silo Wellness Submits CSE Listing Statement for Review of Born Defense Proposed Change of Business

Silo Wellness Inc. (CSE: SILO) ("Silo" or the "Company"), to be renamed Born Defense Inc., is pleased to announce that it has submitted its listing statement (the "Listing Statement") with the Canadian Securities Exchange (the "CSE") on September 26, 2025, for review in connection with its... Keep Reading...
IMARC

Two years of toil has us at new tech tipping point: A conversation with ABB’s Joachim Braun

‘We cannot wait for the perfect solution when we have the tools to make a real difference today’

Apple scores record 72 Emmy Award nominations and sweeps across top categories including Outstanding Limited series for "Lessons in Chemistry," Outstanding Drama for "The Morning Show" and "Slow Horses" and Outstanding Comedy for "Palm Royale"

Apple scores record 72 Emmy Award nominations and sweeps across top categories including Outstanding Limited series for "Lessons in Chemistry," Outstanding Drama for "The Morning Show" and "Slow Horses" and Outstanding Comedy for "Palm Royale"

With best-ever Emmy showing, Apple TV+ lands nominations across 16 Apple Originals including "Lessons in Chemistry," "The Morning Show," "Slow Horses," "Palm Royale," "Loot," "Hijack," "STEVE! (martin) a documentary in 2 pieces," "Girls State," "The Reluctant Traveler With Eugene Levy," "Masters... Keep Reading...
Snowflake Furthers Leadership as the Best Data Foundation for Enterprises

Snowflake Furthers Leadership as the Best Data Foundation for Enterprises

Customers now gain increased interoperability with open data, governed internal collaboration, and enhanced efficiency with new advancements to Snowflake's leading platform Snowflake (NYSE: SNOW), the AI Data Cloud company, today announced at its annual user conference, Snowflake Summit 2024 ,... Keep Reading...
Snowflake Unveils Polaris Catalog and Emphasizes Commitment to Interoperability with AWS, Google Cloud, Microsoft Azure, Salesforce, and More

Snowflake Unveils Polaris Catalog and Emphasizes Commitment to Interoperability with AWS, Google Cloud, Microsoft Azure, Salesforce, and More

Open catalog for Apache Iceberg helps organizations gain control and flexibility over their enterprise data Snowflake (NYSE: SNOW), the AI Data Cloud company, today announced at its annual user conference, Snowflake Summit 2024 , Polaris Catalog , a vendor-neutral, open catalog implementation... Keep Reading...
Sona Nanotech

Sona Nanotech Grants Options

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") is pleased to announce that it has granted 25,000 incentive stock options under the Company's Stock Option Plan ("Option Plan") to a consultant. Each option is exercisable into one common share at a price of $0.30 per share... Keep Reading...
Sona Nanotech

Sona Nanotech

Get access to more exclusive Nanotech Investing Stock profiles here Keep Reading...
Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron to Present at the Emerging Growth Virtual Conference on June 12, 2024

Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative medicines, today announced that it will participate in the Emerging Growth Virtual Conference taking place June 12-13, 2024. Details for the Company's presentation: Date: Wednesday, June 12, 2024 Time:... Keep Reading...
Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company will present two... Keep Reading...
Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

Dr. Selvaggi was instrumental in the development and approval of lung cancer drugs Zykadia for Novartis and Opdivo for Bristol Myers Squibb CEL-SCI's Multikine immunotherapy improves the 5-year survival of head and neck cancer patients to 73% compared to 45% in controls and cuts the 5-year risk... Keep Reading...

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

VTX3232 demonstrated improvements in body weight, systemic inflammatory biomarkers and cardiometabolic parameters in diet-induced obesity (DIO) mice Additive effects were observed for VTX3232 in combination with the GLP-1 receptor agonist semaglutide across key endpoints compared to semaglutide... Keep Reading...

Latest Press Releases

Related News